Transaction DateRecipientSharesTypePriceValue
29th January 2021Beth Hecht150,000Grant/award etc.$0.00
30th June 2020Beth Hecht3,731Grant/award etc.$2.26$8,432.06
10th June 2020Beth Hecht23,453Grant/award etc.$0.00
10th June 2020Gregory J Robitaille23,453Grant/award etc.$0.00
10th June 2020James A. Jr. Robinson23,453Grant/award etc.$0.00
10th June 2020John P. Schmid23,453Grant/award etc.$0.00
10th June 2020Bryant Fong23,453Grant/award etc.$0.00
10th June 2020Alan L Heller23,453Grant/award etc.$0.00
10th June 2020Linda M Szyper23,453Grant/award etc.$0.00
13th March 2020Beth Hecht4,000Open or private purchase$1.97$7,880.00
Neos Therapeutics
Neos Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.

Neos Therapeutics, Inc is a pharmaceutical company focused on developing, manufacturing and commercializing products. The firm manufactures and markets its generic version of the branded product Tussionex. The company was founded by Darlene R. Ryan on November 30, 1994 and is headquartered in Grand Prairie, TX.

Ticker: NEOS
Sector: Health Technology
Industry: Pharmaceuticals: Other
SEC Central Index Key (CIK): 1467652
Employees: 213
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $13 M (-24%)
Inventory, Net: $9 M (0%)
Assets, Current: $40 M (-39%)
Property, Plant and Equipment, Net: $7 M (-9%)
Other Assets, Noncurrent: $1 M (-17%)
Assets: $63 M (-31%)
Accounts Payable, Current: $9 M (42%)
Accrued Liabilities, Current: $26 M (0%)
Liabilities, Current: $61 M (-3%)
Other Liabilities, Noncurrent: $154 Th (-3%)
Common Stock, Value, Issued: $50 Th (0%)
Common Stock, Shares, Issued: $50 M (0%)
Retained Earnings (Accumulated Deficit): $347 M (0%)
Stockholders' Equity (Parent): $16 M (0%)
Liabilities and Equity: $63 M (-31%)
Revenue: $13 M (0%)
Cost of Revenue: $6 M (-52%)
Gross Margin: $7 M (-52%)
Research and Development: $1 M (-60%)
Sales and Marketing: $5 M (-59%)
General and Administrative Expenses: $4 M (-54%)
Operating Income/Loss: $3 M (-67%)